Stanford Cancer Institute shared a post on LinkedIn:
“A two-headed molecule designed by Stanford Medicine researchers hijacks one of the most common protein drivers of B-cell lymphoma, flipping it from its role as a promoter of cell growth into an arbiter of cell death. In mice, a short course of twice-a-day treatment eliminated aggressive lymphoma tumors within 11 days.
The approach builds on a strategy the researchers have been refining for several years: Rather than trying to block a cancer-causing protein, they engineer a small molecule that physically links the culprit with another molecule that switches on the cell’s own self-destruct program. A similar approach may work for other types of cancers and autoimmune diseases, the researchers believe.
‘We’re trying to essentially fight cancer with its cause — taking the driving force of the cancer and then rewiring it to activate cell death mechanisms,’ said Stanford Cancer Institute member Gerald Crabtree, the David Korn, Professor in Pathology and a professor of developmental biology.”
You can also read: AbbVie and Genmab Report 51% Reduction in Progression With Epcoritamab Plus R-CHOP in Diffuse Large B-cell Lymphoma
